Reverse DCF
What growth does the market imply for JBCHEPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
very aggressive
21.3% implied annual FCF growth
The market is pricing in exceptional growth that only a handful of companies sustain for a decade. For context, this company has historically grown at 7.3%. High execution risk.
Current Price
₹2,202
Historical Growth
7.3%
FCF Yield
1.76%
Price / FCF
56.9x
Plain English
To justify today's price of ₹2201.50, JBCHEPHARM.NS needs to grow its free cash flow at 21.3% per year for the next 10 years. That is 14.0% faster than its historical growth rate of 7.3%. At its historical growth rate, the stock cannot justify its current price within a 20-year horizon. The market is pricing in a step-change in performance.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 7.3% | ₹749 | -66.0% |
| GDP rate | 10.0% | ₹922 | -58.1% |
| Half implied | 10.7% | ₹970 | -55.9% |
| Implied | 21.3% | ₹2,202 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 7.3% growth, the model values JBCHEPHARM at ₹749, below today's ₹2,202.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.